Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS)

Next Previous
X
Search
Trial Profile

A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Lisaftoclax (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; B-cell leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; T-cell leukaemia
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 23 May 2024 According to an Ascentage Pharma media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place on May 31-June 4, 2024 in Chicago, IL.
    • 23 May 2024 Results presented in an Ascentage Pharma Media Release.
    • 23 Oct 2023 Planned End Date changed from 30 Oct 2023 to 30 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top